Point-of-Care Testing Devices: Regulatory Requirements for In-Clinic Diagnostics
Rapid antigen tests, glucose monitoring strips, portable HbA1c analysers, and bedside coagulation testers have made point-of-care diagnostics a routine part of clinic and hospital workflow. These devices fall under India’s in vitro diagnostic device regulations, and the compliance bar for bringing a new point-of-care testing device into a clinic has tightened noticeably over the past two years.
Where Point-of-Care Devices Sit in India’s Regulatory Structure
In vitro diagnostic devices, including point-of-care testing kits, are regulated under the Medical Device Rules, 2017, and are subject to the same four-tier, risk-based classification used for other medical devices, running from Class A at the lowest risk to Class D at the highest. CDSCO updated its risk-based IVD classification framework in 2023, and most point-of-care tests for common conditions fall into the low-to-moderate Class A or B categories, while tests used to diagnose serious infectious diseases or guide high-stakes treatment decisions can sit at Class C or above.
Since October 2023, all Class C and Class D devices, including higher-risk IVDs, require a valid CDSCO licence even if they were previously treated as non-notified, closing a gap that many diagnostic device categories had operated in for years.
India-Specific Performance Data Is Now Non-Negotiable
A point-of-care device holding US FDA clearance or EU IVDR CE marking is not automatically approved for the Indian market. CDSCO requires India-specific performance evaluation data before a device can be licensed for import or manufacture, reflecting the reality that disease prevalence, patient population characteristics, and testing conditions in India can differ from those in the markets where the device was originally validated.
For high-priority disease categories such as tuberculosis, dengue, malaria, influenza, HIV, hepatitis B, and hepatitis C, ICMR and CDSCO have jointly issued dozens of standardised evaluation protocols with defined acceptance thresholds, and CDSCO maintains an updated list of authorised laboratories mapped to each disease category where this performance evaluation must be conducted.
What Clinics Should Verify Before Adopting a New Device
Before bringing a new point-of-care testing device into clinical use, a clinic should confirm the manufacturer or importer holds a current CDSCO licence appropriate to the device’s IVD risk class, verify the licence through the SUGAM portal rather than relying solely on the vendor’s documentation, and check that the device has undergone India-specific performance evaluation where the disease category requires it.
Clinics should also be cautious with devices marketed heavily on international regulatory approvals alone, since a CE mark or FDA clearance says nothing about whether the device has cleared CDSCO’s separate Indian licensing requirement. Using an unlicensed IVD device, even one approved elsewhere, exposes the clinic to regulatory risk if a patient outcome is later questioned.
Software-Connected Point-of-Care Devices Add a Layer
Many newer point-of-care analysers connect to a companion app or cloud dashboard that interprets results or flags abnormal readings. Where this software performs a genuine diagnostic or interpretive function independent of the hardware, it may itself be classified as Software as a Medical Device under CDSCO’s finalised Medical Device Software guidance, meaning the software component can carry its own separate licensing obligation distinct from the physical test device.
Clinics adopting connected point-of-care systems should ask vendors directly whether the accompanying software has been separately classified and licensed, rather than assuming that hardware approval automatically covers the software layer.
Conclusion
Point-of-care testing has genuinely improved same-visit clinical decision-making, but the regulatory bar for these devices in India is no longer light-touch. A quick licence and performance-data check before adoption protects both patient safety and the clinic’s own compliance position, and takes only a few minutes against the SUGAM portal’s public device records.
Researched Resources
1. IVD Regulation Guide 2026 for India, EU & USA
2. Regulatory Framework for In Vitro Diagnostic Devices in India
3. Medical Device Registration in India with CDSCO Guide 2026
4. Medical Device Regulation India: CDSCO Guide 2026
Disclaimer: This article is for general informational and educational purposes and reflects CDSCO’s in vitro diagnostic device regulatory framework as understood at the time of writing; classification lists and licensing procedures continue to evolve. It is not regulatory or legal advice, and clinics should confirm specific device licensing status directly with CDSCO or a qualified regulatory consultant.
Vivek Chaudhary is a Technical Content Developer specializing in healthcare, health technology, and digital healthcare business solutions. He creates research-driven, SEO-focused content for doctors, clinics, hospitals, healthcare professionals, and patients, covering topics such as healthcare technology, patient engagement, clinic management, digital communication, and online visibility.
